SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 75 filers reported holding SYNDAX PHARMACEUTICALS INC in Q3 2018. The put-call ratio across all filers is 0.13 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,303,359 | -32.8% | 227,504 | -3.2% | 0.00% | 0.0% |
| Q2 2023 | $4,918,131 | +10.0% | 234,980 | +11.0% | 0.00% | 0.0% |
| Q1 2023 | $4,471,590 | -8.7% | 211,723 | +10.0% | 0.00% | 0.0% |
| Q4 2022 | $4,898,692 | +7.7% | 192,483 | +1.7% | 0.00% | 0.0% |
| Q3 2022 | $4,547,000 | +41.3% | 189,194 | +13.2% | 0.00% | 0.0% |
| Q2 2022 | $3,217,000 | +4.9% | 167,187 | -5.2% | 0.00% | 0.0% |
| Q1 2022 | $3,066,000 | -15.9% | 176,391 | +5.9% | 0.00% | 0.0% |
| Q4 2021 | $3,647,000 | +13.3% | 166,572 | -1.1% | 0.00% | 0.0% |
| Q3 2021 | $3,218,000 | +27.5% | 168,350 | +14.6% | 0.00% | – |
| Q2 2021 | $2,524,000 | -13.5% | 146,945 | +12.6% | 0.00% | -100.0% |
| Q1 2021 | $2,918,000 | +0.5% | 130,515 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $2,903,000 | +90.0% | 130,515 | +26.0% | 0.00% | – |
| Q3 2020 | $1,528,000 | -0.4% | 103,559 | +0.0% | 0.00% | – |
| Q2 2020 | $1,534,000 | +69.3% | 103,541 | +25.3% | 0.00% | – |
| Q1 2020 | $906,000 | +37.7% | 82,622 | +10.2% | 0.00% | – |
| Q4 2019 | $658,000 | +21.9% | 74,987 | +3.7% | 0.00% | – |
| Q3 2019 | $540,000 | -18.1% | 72,345 | +2.0% | 0.00% | – |
| Q2 2019 | $659,000 | +89.9% | 70,899 | +7.3% | 0.00% | – |
| Q1 2019 | $347,000 | +20.1% | 66,062 | +1.6% | 0.00% | – |
| Q4 2018 | $289,000 | -28.1% | 65,036 | +30.7% | 0.00% | – |
| Q3 2018 | $402,000 | -28.7% | 49,762 | -38.1% | 0.00% | – |
| Q2 2018 | $564,000 | -14.7% | 80,372 | +72.9% | 0.00% | – |
| Q1 2018 | $661,000 | +66.9% | 46,480 | +2.9% | 0.00% | – |
| Q4 2017 | $396,000 | -28.8% | 45,176 | -5.0% | 0.00% | – |
| Q3 2017 | $556,000 | -9.6% | 47,532 | +8.0% | 0.00% | – |
| Q2 2017 | $615,000 | +53.4% | 44,025 | +50.6% | 0.00% | – |
| Q1 2017 | $401,000 | +174.7% | 29,227 | +43.5% | 0.00% | – |
| Q4 2016 | $146,000 | -42.3% | 20,366 | +22.4% | 0.00% | – |
| Q3 2016 | $253,000 | – | 16,641 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 1,025,000 | $21,648,000 | 10.42% |
| Foresite Capital Management IV, LLC | 875,000 | $18,480,000 | 9.59% |
| Kynam Capital Management, LP | 3,205,986 | $67,710,424 | 8.74% |
| Frazier Life Sciences Management, L.P. | 3,708,838 | $78,330,659 | 5.67% |
| ACUTA CAPITAL PARTNERS, LLC | 330,000 | $6,969,600 | 5.13% |
| Paradigm Biocapital Advisors LP | 2,274,512 | $48,037,693 | 4.55% |
| Eversept Partners, LP | 2,209,057 | $46,655,284 | 3.25% |
| DAFNA Capital Management LLC | 447,073 | $9,442,182 | 2.83% |
| COMMODORE CAPITAL LP | 853,884 | $18,034,030 | 2.75% |
| Avidity Partners Management LP | 3,865,300 | $81,635,136 | 2.71% |